Therapeutic Asset Ratings

3,774 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
cd22 car-transduced t cells Acute Lymphoblastic Leukemia	National Cancer Institute (NCI)	P2	B (56)
Chimeric Antigen Receptor Modified T Cells Infusion Leukemia	Princess Maxima Center for Pediatric Oncology	P2	B (56)
Ciml-Nk Cells Acute Myeloid Leukemia	Children's Hospital Medical Center, Cincinnati	P2	B (56)
Lifileucel Triple-Negative Breast Carcinoma	Yale University	P2	B (56)
TIL Colorectal Cancer	City of Hope Medical Center	P2	B (56)
Treg Cells Hematopoietic And Lymphoid System Neoplasm	Stanford University	P2	B (56)
Treg Cells Amyotrophic Lateral Sclerosis	The Methodist Hospital Research Institute	P2	B (56)
cd22 car-transduced t cells Non-Hodgkin Lymphoma	Tongji Hospital	P1	B (56)
cd19/cd20 dual-car-t cells B-Cell Non-Hodgkin Lymphoma	Beijing Tsinghua Chang Gung Hospital	P1/2	B (56)
Chimeric Antigen Receptor Modified T Cells Infusion Diffuse Large B Cell Lymphoma	University of Texas Southwestern Medical Center	P1/2	B (56)
her2bbζ/cd19t+ t cells Acute Myeloid Leukemia	David Avigan	P1/2	B (56)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Acute Myeloid Leukemia	Leland Metheny	P2	CCC (55)
ALLOGENEIC HUMAN UMBILICAL CORD BLOOD Chronic Myelomonocytic Leukemia	Leland Metheny	P2	CCC (55)
Anti-Cd19 Car T-Cells B-Cell Acute Lymphoblastic Leukemia	Vinmec Research Institute of Stem Cell and Gene Technology	P2	CCC (55)
e7 tcr-t cells Anal Carcinoma	Christian Hinrichs	P2	CCC (55)
her2bbζ/cd19t+ t cells Melanoma	M.D. Anderson Cancer Center	P2	CCC (55)
Hpc, Cord Blood Myelodysplastic Syndrome	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Hpc, Cord Blood Non-Hodgkin Lymphoma	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Human Cmv Pp65-Lamp Mrna-Pulsed Autologous Dcs Glioblastoma	Annick Desjardins, MD	P2	CCC (55)
Inkt Cells Hepatocellular Carcinoma	Beijing YouAn Hospital	P2	CCC (55)
TIL Cervical Cancer	City of Hope Medical Center	P2	CCC (55)
TIL Gastric Cancer	Intima Bioscience, Inc.	P2	CCC (55)
TIL Pancreatic Neoplasm	Intima Bioscience, Inc.	P2	CCC (55)
Wu-Cart-007 Lymphoblastic Lymphoma	Wugen, Inc.	P2	CCC (55)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Myeloproliferative Neoplasm	David Wald	P1/2	CCC (55)

Showing 176 to 200 of 3,774 assets

PreviousPage 8 of 151Next